What is the current valuation of the Japan pain relief-medication market as of 2024?

The market valuation was $4100.0 Million in 2024. Read More

What is the projected market size for the Japan pain relief-medication market by 2035?

The market is expected to reach $9000.0 Million by 2035. Read More

What is the expected CAGR for the Japan pain relief-medication market during the forecast period 2025 - 2035?

The expected CAGR is 7.41% during the forecast period 2025 - 2035. Read More

Which segment generated the highest revenue in the Japan pain relief-medication market in 2024?

The Non-Steroidal Anti-Inflammatory Drugs segment generated $1500.0 Million in 2024. Read More

How does the revenue of Acetaminophen compare to Opioids in the Japan pain relief-medication market?

Acetaminophen generated $1200.0 Million, while Opioids generated $800.0 Million in 2024. Read More

What formulation type is projected to have the highest revenue in the Japan pain relief-medication market by 2035?

Tablets are projected to generate the highest revenue, reaching $3200.0 Million by 2035. Read More

What is the revenue range for the Injectable route of administration in the Japan pain relief-medication market?

The revenue for Injectable administration ranged from $1200.0 Million to $2500.0 Million in 2024. Read More

Which therapeutic area is expected to see the most growth in the Japan pain relief-medication market by 2035?

Chronic Pain is expected to see substantial growth, with a projected revenue of $3200.0 Million by 2035. Read More

Who are the key players in the Japan pain relief-medication market?

Key players include Johnson & Johnson, Pfizer, Bayer, and GlaxoSmithKline, among others. Read More

What is the revenue range for Topical formulations in the Japan pain relief-medication market?

Topical formulations generated between $600.0 Million and $1500.0 Million in 2024. Read More

Japan Pain Relief Medication Market

Japan Pain Relief Medication Market Research Report: Size, Share, Trend Analysis By Medication Type (Non-Steroidal Anti-Inflammatory Drugs, Acetaminophen, Opioids, Adjuvant Analgesics), By Formulation Type (Tablets, Capsules, Liquid, Topical), By Route of Administration (Oral, Topical, Injectable, Transdermal) and By Therapeutic Area (Chronic Pain, Acute Pain, Postoperative Pain, Cancer Pain) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

7.41%

2024 Market Size

$ 4,100 Million

2035 Market Size

$ 9,000 Million

Medical Device ● Updated August 2026 Report ID: MRFR/MED/49333-HCR | Pages: 200 | Author: Nidhi Mandole, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Construction, BY Type (USD Million) | |
  1. 4.1.1 Non-Steroidal Anti-Inflammatory Drugs | |
  2. 4.1.2 Acetaminophen | |
  3. 4.1.3 Opioids | |
  4. 4.1.4 Adjuvant Analgesics |
2. 4.2 Construction, BY Formulation Type (USD Million) | |
  1. 4.2.1 Tablets | |
  2. 4.2.2 Capsules | |
  3. 4.2.3 Liquid | |
  4. 4.2.4 Topical |
3. 4.3 Construction, BY Route of Administration (USD Million) | |
  1. 4.3.1 Oral | |
  2. 4.3.2 Topical | |
  3. 4.3.3 Injectable | |
  4. 4.3.4 Transdermal |
4. 4.4 Construction, BY Therapeutic Area (USD Million) | |
  1. 4.4.1 Chronic Pain | |
  2. 4.4.2 Acute Pain | |
  3. 4.4.3 Postoperative Pain | |
  4. 4.4.4 Cancer Pain 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Construction | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Johnson & Johnson (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Pfizer (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Bayer (DE) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 GlaxoSmithKline (GB) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 AbbVie (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 AstraZeneca (GB) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Sanofi (FR) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Novartis (CH) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Teva Pharmaceutical Industries (IL) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 JAPAN MARKET ANALYSIS BY TYPE |
6. 6.3 JAPAN MARKET ANALYSIS BY FORMULATION TYPE |
7. 6.4 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
8. 6.5 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA |
9. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION |
10. 6.7 RESEARCH PROCESS OF MRFR |
11. 6.8 DRO ANALYSIS OF CONSTRUCTION |
12. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION |
13. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION |
14. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION |
15. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE) |
16. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million) |
17. 6.14 CONSTRUCTION, BY FORMULATION TYPE, 2024 (% SHARE) |
18. 6.15 CONSTRUCTION, BY FORMULATION TYPE, 2024 TO 2035 (USD Million) |
19. 6.16 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
20. 6.17 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million) |
21. 6.18 CONSTRUCTION, BY THERAPEUTIC AREA, 2024 (% SHARE) |
22. 6.19 CONSTRUCTION, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million) |
23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
24. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
25. 7.2 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million) | |
  2. 7.2.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  4. 7.2.4 BY THERAPEUTIC AREA, 2025-2035 (USD Million) |
26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.3.1 |
27. 7.4 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Japan Pain Relief Medication Market Segmentation

Japan Pain Relief Medication Market By Type (USD Million, 2025-2035)

Non-Steroidal Anti-Inflammatory Drugs
Acetaminophen
Opioids
Adjuvant Analgesics

Japan Pain Relief Medication Market By Formulation Type (USD Million, 2025-2035)

Tablets
Capsules
Liquid
Topical

Japan Pain Relief Medication Market By Route of Administration (USD Million, 2025-2035)

Oral
Topical
Injectable
Transdermal

Japan Pain Relief Medication Market By Therapeutic Area (USD Million, 2025-2035)

Chronic Pain
Acute Pain
Postoperative Pain
Cancer Pain

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”